There was no significant difference between concurrent and sequential groups in cardiac event rates ( 9.1 % vs13 .0 % , P = 0.556 ) , neither of LVEF values at basline or at 3 , 6 , 9 and 12 months during trastuzumab treatment ( P > 0.05 ) .